Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- Lehman -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (22)	4/4/2003 11:54:12 AM
From: tuck	Respond to of 30

Birchenough and I disagree on CTIC: >>Lehman Brothers analyst Jim Birchenough believes Cell Therapeutics is a better-run company with the new employees brought in, especially those on the clinical side. But, he acknowledges, "It would have been better for [Cell Therapeutics] to be as open and public as possible about the upgrade of personnel." He rates Cell Therapeutics overweight and his firm doesn't do banking for the company.<< Snipped from Street.com Feuerstein piece. So far, Birchenough is winning. Cheers, Tuck